Monopar board: Michael Brown resigns, Lavina Talukdar appointed

Monopar Therapeutics

Michael J. Brown resigned from the Board effective February 19, 2025.
Lavina Talukdar appointed to the Board effective February 21, 2025.
Talukdar also named to Audit, Compensation, Governance, and Plan Administration Committees.
Talukdar is SVP, Head of Investor Relations at Moderna, with 20+ years of experience.
She will receive standard compensation for non-employee directors.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lavina Talukdar

Director

MNPR · Monopar Therapeutics

Effective: 2025-02-21
Filed: February 24, 2025, 6:59 PM ET

On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.

Departed

Michael J. Brown

Director

MNPR · Monopar Therapeutics

Effective: 2025-02-19
Filed: February 24, 2025, 6:59 PM ET

Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lavina Talukdar was appointed as Director at Monopar Therapeutics.

Action: appointed
Role: Director

Exact text from the filing

On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael J. Brown resigned as Director at Monopar Therapeutics.

Action: resigned
Role: Director

Exact text from the filing

Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.

View on SEC.gov

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-25-004910

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.